RT Journal Article
SR Electronic
T1 Anticholinergic burden in middle and older age is associated with lower cognitive function, but not with brain atrophy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.04.22279576
DO 10.1101/2022.09.04.22279576
A1 Mur, J.
A1 Marioni, R. E.
A1 Russ, T. C.
A1 Muniz-Terrera, G.
A1 Cox, S. R.
YR 2022
UL http://medrxiv.org/content/early/2022/09/12/2022.09.04.22279576.abstract
AB Background Anticholinergic drugs block muscarinic receptors in the body. They are commonly prescribed for a variety of indications and their use has previously been associated with dementia and cognitive decline.Methods UK Biobank participants with linked health-care records (n=163,043, aged 40-71 at baseline), for about 17,000 of which MRI data was available, we calculated the total anticholinergic drug burden according to 15 different anticholinergic scales and due to different classes of drugs. We then used linear regression to explore the associations between anticholinergic burden and various measures of cognition and structural MRI, including general cognitive ability, 9 separate cognitive domains, brain atrophy, volumes of 68 cortical and 14 subcortical areas, and fractional anisotropy and median diffusivity of 25 white-matter tracts.Results Anticholinergic burden was modestly associated with poorer cognition across most anticholinergic scales and cognitive tests (7/9 FDR-adjusted significant associations, standardised betas (β) range: −0.039, −0.003). When using the anticholinergic scale exhibiting the strongest association with cognitive functions, anticholinergic burden due to only some classes of drugs exhibited negative associations with cognitive function, with β-lactam antibiotics (β=-0.035, pFDR<0.001) and opioids (β=-0.026, pFDR<0.001) exhibiting the strongest effects. Anticholinergic burden was not associated with any measure of brain macro- or microstructure (pFDR>0.08).Discussion Anticholinergic burden is weakly associated with poorer cognition, but there is little evidence for associations with brain structure. Future studies might focus more broadly on polypharmacy or more narrowly on distinct drug classes, instead of using purported anticholinergic action to study the effects of drugs on cognitive ability.Competing Interest StatementREM has received consulting fees from the Epigenetic Clock Development Foundation and speaker fees from Illumina. TCR has received fees for medicolegal work from private solicitors. SRC has received speaker fees from the Society of Biological Psychiatry. GMT has received consulting fees for grants funded by the NIH. JM has nothing to disclose.Funding StatementThis research was funded in whole, or in part, by the Wellcome Trust [108890/Z/15/Z]. For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission. REM is supported by Alzheimer's Research UK major project grant ARUK-PG2017B-10 and by an Alzheimer's Society major project grant AS-PG-19b-010. JM is supported by funding from the Wellcome Trust 4‐year PhD in Translational Neuroscience-training the next generation of basic neuroscientists to embrace clinical research [108890/Z/15/Z]. JM and TCR are members of the Alzheimer Scotland Dementia Research Centre funded by Alzheimer Scotland.TCR is employed by NHS Lothian and the Scottish Government and has received grants from the Royal Society of Edinburgh [1689], the Scottish Government, the Chief Scientist Office [NRS NDN and CGA/19/05], the UK National Health Service, and UK Research and Innovation [ES/W001349/1]. SRC is supported by a Sir Henry Dale Fellowship, jointly funded by the Wellcome Trust and the Royal Society [221890/Z/20/Z] and has received grants from Age UK [The Disconnected Mind project], the UK Medical Research Council [MR/R024065/1], the National Institutes of Health [R01AG054628; 1RF1AG073593] and the UK Biotechnology and Biological Sciences Research Council and the Economic and Social Research Council (BB/W008793/1; ES/T003669/1). GMT has received funding from the Medical Research Council Methodology Board.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Research Ethics Committee (REC) of the Univeristy of Edinburgh granted ethical approval for the study (reference 11/NW/0382) and the current analysis was conducted under data application 10279.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon request from UK Biobank. https://github.com/JuM24/UKB-AChB-cognition-MRI